Stock Analysis of Alector Inc (ALEC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ALEC
Close 5.44
Change -0.0500 / 0.911 %
Volume 544593
Vol Change 67480.00 / 14.14 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Alector Inc
PE (TTM)

-947.11

Very Poor
Price / Book

668.08

Very Poor
Price / Sales

1184.92

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

524332 K

Enterprise Value

458239 K

ROA (TTM)

-17.81

Very Poor
ROE (TTM)

-70.54

Very Poor
Net Margin (TTM)

-125.11

Very Poor
Revenue

27.92 %

96312.00 K
Net Profit

6.06 %

-141385.00 K
Debt to Equity

0.063

Excellent
Altman Z Score

-0.801

Very Poor
Quick Ratio

0

Poor
Cash Ratio

3.08

Very Good


Highs/Lows of Alector Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.25 3.62 % 1.54 % 5.695.2516-May-2414-May-24
Two Week5.39 0.928 % 3.42 % 5.695.0516-May-2409-May-24
One Month5.07 7.30 % 5.60 % 5.694.816-May-2425-Apr-24
Three Month6.37 14.60 % 5.95 % 7.57734.828-Feb-2425-Apr-24
Six Months4.31 26.22 % 17.48 % 8.94.2809-Jan-2420-Nov-23
One year7.62 28.61 % 27.52 % 9.0653.6604-Aug-2316-Nov-23
Two year9.11 40.29 % 29.70 % 10.073.6630-Sep-2216-Nov-23
Five year20.31 73.22 % 85.46 % 9.863.6617-Feb-2316-Nov-23


Technical View of Alector Inc
RSI

49.91

Neutral
MACD

-0.053

Bullish
ADX

13.89

Mild Bearish
Super Trend

5.91

Mild Bearish
Williams %R

-30.12

Neutral
CCI

69.67

Strong Bearish


EMA 5

5.44

Strong Bearish
EMA 15

5.38

Bullish
EMA 50

5.64

Mild Bearish
EMA 100

5.91

Mild Bearish
SMA 100

6.22

Mild Bearish
SMA 200

6.15

Strong Bearish
SMA 5 / 20

5.46 / 5.29

Mild Bullish
SMA 15 / 50

5.33 / 5.67

Mild Bearish
SMA 50 / 200

5.67 / 6.15

Bearish




Charts of Alector Inc


Returns of Alector Inc with Peers
Period / StockALECIRMDADPTATXS
1 Week3.62%-3.58%3.14%-1.95%
1 Mth7.30%3.85%47.95%-9.57%
3 Mth-14.60%-7.59%-6.23%-31.71%
6mth26.22%-0.450%-16.24%115.84%
1 Year-28.61%-8.31%-42.24%-22.82%
2 Year-40.29%28.18%-56.03%130.43%
5 Years-73.22%86.72%--80.03%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Alector Inc with Peers
Ratio / StockALECIRMDADPTATXS
PE-947.1129.87-2.43-4.36
P/B668.087.531.481.48
ROA-17.8121.10-30.25-32.58
ROE-70.5425.21-60.92-33.81
Debt To Equity0.0630.00600.03040.0014
Revenue96312.00 K
27.92 % 		62973.71 K
18.14 % 		179690 K
3.03 % 		0
%
Net Income-141385.00 K
6.06 % 		16326.71 K
27.28 % 		-195937.00 K
2.12 % 		-54744.00 K
5.61 %


Technicals of Alector Inc with Peers
Technical / StockALECIRMDADPTATXS-
ADX13.8920.1930.7018.88
CMF-0.102-0.064-0.0186-0.095
MFI62.9847.2369.9054.38
RSI49.9147.1860.1141.66
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MAFalseFalseFalseTrue-


About : Alector Inc

Address : 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Tel : 415 231 5660
URL : https://www.alector.com
Code : ALEC, ISIN : US0144421072, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_Feb_2019
Employee Count : 244

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)